Cullinan Therapeutics has dosed the first patient in its planned registrational Phase 2 trial of CLN-049 for relapsed or refractory acute myeloid leukemia. The investigational FLT3 T-cell engager is being evaluated for efficacy and safety.
published
Cullinan Therapeutics has dosed the first patient in its planned registrational Phase 2 trial of CLN-049 for relapsed or refractory acute myeloid leukemia. The investigational FLT3 T-cell engager is being evaluated for efficacy and safety.
Latest documented BWB result
$AAPL market result
I sold the $AAPL $320 Puts for 11/20 - $5.30
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.